Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)

A. Gualberto; M. L. Hixon; D. D. Karp; D. Li; S. Green; M. Dolled-Filhart; L. G. Paz-Ares; S. Novello; J. Blakely; C. J. Langer; M. N. Pollak

doi:10.1038/bjc.2012.497

Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)

A. Gualberto, M. L. Hixon, D. D. Karp, D. Li, S. Green, M. Dolled-Filhart, L. G. Paz-Ares, S. Novello, J. Blakely, C. J. Langer, M. N. Pollak

Investigational Cancer Therapeutics

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	2024
Number of pages	1
Journal	British journal of cancer
Volume	107
Issue number	12
DOIs	https://doi.org/10.1038/bjc.2012.497
State	Published - Dec 4 2012

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2012.497

Cite this

Gualberto, A., Hixon, M. L., Karp, D. D., Li, D., Green, S., Dolled-Filhart, M., Paz-Ares, L. G., Novello, S., Blakely, J., Langer, C. J., & Pollak, M. N. (2012). Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972). British journal of cancer, 107(12), 2024. https://doi.org/10.1038/bjc.2012.497

Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972). / Gualberto, A.; Hixon, M. L.; Karp, D. D. et al.
In: British journal of cancer, Vol. 107, No. 12, 04.12.2012, p. 2024.

Research output: Contribution to journal › Comment/debate › peer-review

Gualberto, A, Hixon, ML, Karp, DD, Li, D, Green, S, Dolled-Filhart, M, Paz-Ares, LG, Novello, S, Blakely, J, Langer, CJ & Pollak, MN 2012, 'Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)', British journal of cancer, vol. 107, no. 12, pp. 2024. https://doi.org/10.1038/bjc.2012.497

@article{250b244c09cf4abc8eaa328b9862c831,

title = "Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)",

author = "A. Gualberto and Hixon, {M. L.} and Karp, {D. D.} and D. Li and S. Green and M. Dolled-Filhart and Paz-Ares, {L. G.} and S. Novello and J. Blakely and Langer, {C. J.} and Pollak, {M. N.}",

year = "2012",

month = dec,

day = "4",

doi = "10.1038/bjc.2012.497",

language = "English (US)",

volume = "107",

pages = "2024",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Erratum

T2 - Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)

AU - Gualberto, A.

AU - Hixon, M. L.

AU - Karp, D. D.

AU - Li, D.

AU - Green, S.

AU - Dolled-Filhart, M.

AU - Paz-Ares, L. G.

AU - Novello, S.

AU - Blakely, J.

AU - Langer, C. J.

AU - Pollak, M. N.

PY - 2012/12/4

Y1 - 2012/12/4

UR - http://www.scopus.com/inward/record.url?scp=84870792537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870792537&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.497

DO - 10.1038/bjc.2012.497

M3 - Comment/debate

C2 - 23211971

AN - SCOPUS:84870792537

SN - 0007-0920

VL - 107

SP - 2024

JO - British journal of cancer

JF - British journal of cancer

IS - 12

ER -

Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this